Sopharma AD-Sofia (WAR:SPH) Total Liabilities: zł2,311 Mil (As of Mar. 2026)

What is Sopharma AD-Sofia Total Liabilities?

Sopharma AD-Sofia WAR:SPH 66 Total Liabilities is zł2,311 Mil as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł12.63 (Possible Value Trap). The stock has 4 warning signs investors should review.

Sopharma AD-Sofia's Total Liabilities for the quarter that ended in Mar. 2026 was zł2,311 Mil.

Sopharma AD-Sofia's quarterly Total Liabilities increased from Sep. 2025 (zł2,324.15 Mil) to Dec. 2025 (zł2,464.33 Mil) but then declined from Dec. 2025 (zł2,464.33 Mil) to Mar. 2026 (zł2,311.45 Mil).

Sopharma AD-Sofia's annual Total Liabilities increased from Dec. 2023 (zł1,583.21 Mil) to Dec. 2024 (zł1,907.34 Mil) and increased from Dec. 2024 (zł1,907.34 Mil) to Dec. 2025 (zł2,464.33 Mil).

Sopharma AD-Sofia Total Liabilities Related Terms

Sopharma AD-Sofia Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Total Liabilities Chart

Sopharma AD-Sofia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

1,179.59

1,082.11

1,583.21

1,907.34

2,464.33

Sopharma AD-Sofia Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															2,190.79	2,307.74	2,324.15	2,464.33	2,311.45

66GF Score

Sopharma AD-Sofia WAR:SPH

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sopharma AD-Sofia Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sopharma AD-Sofia's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1936.146	+	(467.539	+	26.067
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	26.264	+	8.317)
	=	2,464

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	4649.551	-	2185.218
	=	2,464

Sopharma AD-Sofia's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1777.071	+	(472.702	+	27.406
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	26.008	+	8.317)
	=	2,311

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	4649.832	-	2338.382
	=	2,311

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of zł2,311 Mil mean?

Sopharma AD-Sofia (WAR:SPH) has a Total Liabilities of zł2,311 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sopharma AD-Sofia and its competitors.

Is Sopharma AD-Sofia's Total Liabilities too high?

Sopharma AD-Sofia's current Total Liabilities is zł2,311 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Sopharma AD-Sofia's Total Liabilities compare to MCK and CAH?

Sopharma AD-Sofia's Total Liabilities of zł2,311 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Medical Distribution company?

A good Total Liabilities depends on the Medical Distribution industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Total Liabilities is zł2,311 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sopharma AD-Sofia stock overvalued right now?

Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł12.63, compared to a current price of zł7.70 — trading 39% below its estimated fair value. The current Total Liabilities is zł2,311 Mil. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Total Liabilities is zł2,311 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.70 is trading 39% below its estimated GF Value™ of zł12.63. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

Total Liabilities: zł2,311 Mil
GF Value™: zł12.63 vs. price of zł7.70 (39% below fair value)
GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Industry Healthcare Medical Distribution

Comparable Companies XBUL:SFT MCK CAH COR ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459 OSTO:ASKER MIL:AMP SHSE:600511 IST:SELEC NZSE:EBO TSE:2784 SHSE:600739 TSE:9987

Other Exchanges 3JR:Germany SFA:Bulgaria

Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756

Website https://www.sopharmagroup.com

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.

66GF Score

Get the complete analysis for WAR:SPH

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.70

Price

zł12.63

GF Value

View WAR:SPH Analysis

See Total Liabilities data for all stocks →